Virios Therapeutics Q1 net loss $1.3M; Long-COVID study enrollment >50%

Dogwood Therapeutics, Inc.

2024-Q1 EPS reported -$0.07

Net loss $1.3M ($0.07/shr) vs $1.5M ($0.08/shr) in Q1 2023; cash $2.4M at March 31, 2024.
R&D expenses $0.3M (down from $0.5M); G&A expenses $1.0M (down from $1.1M).
BHC Long-COVID phase 2 trial (IMC-2) exceeded 50% enrollment; top-line data expected H2 2024.
Preliminary safety shows IMC-2 well tolerated; no serious adverse events reported to date.
Global patent for IMC-2 covering Long-COVID and Alzheimer's published; FM partner discussions ongoing.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Dogwood Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: net income $1.3 million, EPS $0.07 basic and diluted net loss per share.

Period: the first quarter ended March 31, 2024
Net income: $1.3 million
EPS: $0.07 basic and diluted net loss per share
Result: reported results

Exact text from the filing

Virios Therapeutics, Inc. (the “Company”) issued a press release announcing the results of operations for the first quarter ended March 31, 2024.

View on SEC.gov

Browse all earnings releases →

Dogwood Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-24-007474

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.